Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm

Cancer Family

Epithelial Neoplasm

CI-CAN-00000016Explore in graph →

Non-malignant7,525 active trials118 approved drugs1,152 evidence items

NCIt: C3709

Overview
Statistics
Survival
Genomics314
Variants & evidence1152
Drugs206
Trials26878
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (916)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 76–100 of 916 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
· J Clin Invest · 2014 · PMID 24569458 · validated civic_curation pubmed
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
· Sci Transl Med · 2011 · PMID 21430269 · validated civic_curation pubmed
Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
· Oncology · 2014 · PMID 24457318 · validated civic_curation pubmed
Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.
· Int J Exp Pathol · 2005 · PMID 16309541 · validated civic_curation pubmed
Cyclin E in human cancers.
· FASEB J · 1999 · PMID 10224221 · validated civic_curation pubmed
The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis.
· Onco Targets Ther · 2014 · PMID 24623981 · validated civic_curation pubmed
Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.
· Onco Targets Ther · 2014 · PMID 24729716 · validated civic_curation pubmed

Showing 76–100 of 916 publications

← Previous
1
2
3
4
5
…
37
Next →

Alterations of the Notch pathway in lung cancer.

· Proc Natl Acad Sci U S A · 2009 · PMID 20007775 · validated civic_curation pubmed

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

· Science · 2014 · PMID 24578576 · validated civic_curation pubmed

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

· Clin Cancer Res · 2006 · PMID 16818686 · validated civic_curation pubmed

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.

· Int J Cancer · 2008 · PMID 18464292 · validated civic_curation pubmed

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

· J Clin Invest · 2005 · PMID 15630448 · validated civic_curation pubmed

Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.

· Cancer · 2010 · PMID 20336784 · validated civic_curation pubmed

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

· J Clin Oncol · 2007 · PMID 17538160 · validated civic_curation pubmed

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

· J Clin Oncol · 2006 · PMID 16943533 · validated civic_curation pubmed

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

· Br J Cancer · 2007 · PMID 17700571 · validated civic_curation pubmed

p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.

· Ann Surg Oncol · 2010 · PMID 19941080 · validated civic_curation pubmed

TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.

· Radiother Oncol · 2001 · PMID 11325447 · validated civic_curation pubmed

Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.

· Clin Cancer Res · 2011 · PMID 21467160 · validated civic_curation pubmed

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

· Eur J Cancer · 2014 · PMID 24915778 · validated civic_curation pubmed

Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma.

· Oral Oncol · 2003 · PMID 12509970 · validated civic_curation pubmed

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.

· Br J Cancer · 2013 · PMID 23989949 · validated civic_curation pubmed

Rociletinib in EGFR-mutated non-small-cell lung cancer.

· N Engl J Med · 2015 · PMID 25923550 · validated civic_curation pubmed

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.

· Lung Cancer · 2009 · PMID 19157633 · validated civic_curation pubmed

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

· J Thorac Oncol · 2012 · PMID 22551904 · validated civic_curation pubmed